Clinical Trial Update: Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects [Phase 4]

View source ↗

Summary

Phase 4 safety evaluation of inhaled treprostinil after transition from inhaled Ventavis in pulmonary arterial hypertension patients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2013-02-20